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S68Weighing Tumor Biology in Treatment Decisions for
Patients with Non-small Cell Lung Cancer
Frances A. Shepherd, MD, and Rafael Rosell, MDyAbstract: Tumor molecular biology is an increasingly important
consideration when choosing therapy for patients with advanced
non-small cell lung cancer (NSCLC). A number of potential
biological markers are under active investigation in the hope that
it will be possible to identify markers that assist in patient selection
for specific therapies. Distinguishing prognostic from predictive
makers is crucial to the development of customized drug therapy.
Some markers, such as mutations in the tyrosine kinase domain of
the epidermal growth factor receptor (EGFR), are prognostic;
patients with EGFR-mutant NSCLC have prolonged survival
compared with those with wild-type disease, regardless of the
treatment received. Although EGFR mutations are predictive of
response to EGFR tyrosine kinase inhibitor (TKI) therapy, they do
not appear to be predictive of a differential effect on survival. Other
EGFR markers, such as protein expression or gene amplification,
may be better predictors of a survival benefit from EGFR TKI.
HER2 expression status and K-ras mutations provide additional
information that may be useful in evaluating a patient for EGFR
TKI therapy. Biological markers for chemosensitivity and
resistance are also emerging. Patients with an elevated DNA repair
capacity, evidenced by increased tumor expression of excision
repair cross-complementing 1 or ribonucleotide reductase subunit
M1 messenger RNA, may benefit less from cisplatin and
gemcitabine, respectively, than from other agents. Increased levels
of class III beta-tubulin are associated with taxane-resistance, and
K-ras mutations have been associated with a lack of survival benefit
from adjuvant chemotherapy in early stage NSCLC. It is likely that
in the future, clinicians will evaluate a panel of biological markers
in order to customize therapy for individual patients with NSCLC.
Key Words: Non-small cell lung cancer, Epidermal growth
factor receptor (EGFR), Excision repair cross-complementing
1 (ERCC1), Molecular markers, Biology.
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Despite advances in chemotherapy and the developmentof targeted therapies, the prognosis for most patients
with advanced non-small cell lung cancer (NSCLC) remains
poor. Currently, clinicians consider disease stage, patient© Adis Data Information BV. Una
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Journal of Thoraciperformance status, degree of weight loss, and sex as the
most important prognostic factors, and the choice of therapy
is determined by the clinical picture. Significant advances
are, however, being made in NSCLC tumor biology, which
may ultimately lead to customized therapy based as much or
more on the tumor’s molecular characteristics as on the
patient’s clinical condition.
This review examines the prognostic and predictive
markers that are currently being explored in NSCLC
(Table 1). It is important to distinguish predictive and
prognostic factors in this discussion. A marker is prognostic
if it predicts outcome, regardless of the treatment received.
A marker is predictive, however, if it predicts the outcome of
a specific therapy. Before a marker can be classified as
predictive and thus be used to individualize treatment, it
should first be evaluated, if possible, for prognostic ability,
in the absence of the treatment in question. This issue is
particularly germane to the use of the epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKI), but
will also be important as markers of chemosensitivity and
resistance reach the clinic.
MOLECULAR MARKERS AND TARGETED
THERAPY
Epidermal Growth Factor Receptor
The EGFR has emerged as an important marker in
NSCLC, but considerable confusion remains regarding how
to use this marker in clinical decision-making. The EGFR
mutation status determined by gene sequencing, gene copy
number determined by fluorescence in situ hybridization
(FISH), and protein expression determined by immunohis-
tochemistry may each contribute important information
regarding which patients are likely to benefit from EGFR
TKI therapy.
Evidence that EGFR mutations correlated with
response to TKI therapy first emerged in 2004.1,2 Lynch
and colleagues1 identified somatic mutations in the tyrosine
kinase domain of the EGFR gene in specimens from eight
out of nine patients with advanced NSCLC who had
responded to gefitinib compared with none among seven
patients who had not responded to gefitinib ( p< 0.001).
In-vitro analyses demonstrated that the mutations were
associated with enhanced tyrosine kinase activity in
response to epidermal growth factor and increased
sensitivity to gefitinib. Paez and colleagues2 also demon-
strated the presence of somatic mutations in tumor samplesuthorized reproduction of this article is prohibited.
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TABLE 1. Biological Markers and their Potential Application in Non-small Cell Lung Cancer.
Biological Marker Role Potential Application
Beta tubulin High levels associated with taxane resistance Guide chemotherapy choice: taxane-based
versus other chemotherapy
EGFR mutations Predicts response to EGFR TKI therapy
and is a prognostic marker for improved
survival, independent of treatment
Identify patients likely to respond to
EGFR TKI therapy
EGFR gene copy number High gene copy number correlated with
improved survival with EGFR TKI
Identify patients for EGFR TKI therapy
EGFR overexpression EGFR protein expression correlated with
improved survival with EGFR TKI
Identify patients for EGFR TKI therapy
ERCC1 Low levels correlate with prolonged survival
after cisplatin/gemcitabine
Guide chemotherapy choice: platinum-based
versus other chemotherapy
HER2 Increased gene copy number predicts response
to gefitinib in EGFR-positive patients
Complementary to EGFR testing to identify
patients with EGFR TKI therapy
K-ras Mutation associated with lack of response to
EGFR TKI therapy, but prognostic significance
remains unclear
Identify patients unlikely to respond to
EGFR TKI therapy
Lack of survival benefit from adjuvant
chemotherapy also reported
Identify patients unlikely to respond to
adjuvant vinorelbine/cisplatin chemotherapy
RRM1 Low levels correlated with prolonged survival
after cisplatin/gemcitabine
Guide chemotherapy choice: gemcitabine-based
versus other chemotherapy
EGFR, Epidermal Growth Factor Receptor; TKI, tyrosine kinase inhibitor.
Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007 Weighing Tumor Biology for Patients with NSCLCfrom NSCLC patients in the United States and Japan. They
noted a correlation between EGFR mutations and patient
characteristics, with mutations more common among
women, non-smokers, patients from Japan, and patients
with adenocarcinoma. They then evaluated the relationship
between mutation status and response to gefitinib in nine
patients treated with gefitinib using pretreatment tumor
samples. Samples from all five of the responding patients
contained EGFR kinase domain mutations, whereas none of
the samples from the four non-responding patients did
( p¼ 0.0027). On the basis of these data, many hypothesized
that EGFR mutations would be predictive of response
to EGFR TKI therapy, and that screening for these
mutations may be useful to select patients for EGFR TKI
treatment.Copyright © Adis Data Information BV. Una
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FIGURE 1. Survival According to Epidermal Growth Factor
Erlotinib; placebo. p value for interaction 0.97.
 2007 International Association for the Study of Lung CancerThe BR.21 trial was a randomized, placebo-controlled
trial of erlotinib for previously treated, advanced NSCLC.
The response rate in that study was 8.9% in the erlotinib
group and less than 1% in the placebo group ( p< 0.001),
and overall survival was significantly improved with
erlotinib (overall survival 6.7 versus 4.7 months, respect-
ively; p< 0.001). Clinical predictors of response included
female sex, adenocarcinoma, Asian ethnicity, and a
history of not smoking, identical to the characteristics
associated with EGFR mutations in other studies.
Patients with EGFR mutations had a higher response to
erlotinib than did those with wild-type EGFR although the
difference was not significant (15.8 versus 7.4%;
p¼ 0.37).3,4 The survival benefit from erlotinib was not,
however, limited to these patients. Even though womenuthorized reproduction of this article is prohibited.
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Shepherd and Rosell Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007were more likely to harbor mutations, erlotinib reduced the
relative risk of death by 20% in both women and men
(hazard ratio [HR] 0.8 in both groups), and patients with
adenocarcinoma had a similar survival benefit compared
with all others. Patients with EGFR mutations also
experienced a survival benefit from erlotinib, but there
was no differential effect on survival based on the presence
of all mutations identified (Figure 1)4 or the presence of the
classical exon 19 deletions or L858R mutations (Figure 2)5
compared with the benefit achieved by patients who had
wild-type EGFR.4,5
The results from BR.21 suggest that EGFR mutations
are not predictive of a differential effect on survival in
response to treatment with an EGFF TKI, although they are
predictive of response, and that patients with both mutated
and wild-type EGFR have the potential to benefit from
such therapy. It is now becoming clear that these
mutations have prognostic significance, independent of
the treatment received. Sasaki and colleagues6 evaluated
the mutation status of tumors from 95 Asian patients with
surgically treated NSCLC, and found that survival was
significantly longer for those with tumors expressing
EGFR mutations than for those with wild-type gene
expression (Figure 3). Similar findings have been reported
from the TRIBUTE and INTACT trials, which evaluated
the addition of the EGFR TKI erlotinib and gefitinib,
respectively, to first-line chemotherapy for advanced
NSCLC.7,8 Survival was significantly longer for theCopyright © Adis Data Information BV. Una
1.0
0.8
0.6
0.4
0.2
0
0 10 20 30 40 50 60 70 80 90
Pe
rc
en
ta
g
e
EGFR Mut (n=35)
EGFR WT (n=60)
p = 0.0143 Log-rank test
p = 0.0220 Breslow--Gehan--Wilcoxon test
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S7029 patients with EGFR-mutant tumors than for the 199 with
wild-type expression in the TRIBUTE trial ( p< 0.001) and
this was independent of erlotinib therapy.7 Erlotinib had no
significant effect on survival for patients with EGFR
mutations. Similarly, survival was longer for patients
receiving chemotherapy alone who had EGFR-mutant
disease than for those who did not in the INTACT trial
(HR 0.48; 95% confidence interval [CI] 0.29–0.82).8
Gefitinib had no significant effect on survival for patients
with EGFR mutations.
Whereas the presence of EGFR mutations does not
appear to predict a differential effect of EGFR TKI on
survival, other EGFR tests may do so. Both EGFR protein
expression and high gene copy number were associated with
significantly improved survival in response to erlotinib in
BR.21 when compared with placebo.4 For patients with
positive tumor EGFR protein expression, the risk of death
was reduced 32% with erlotinib compared with placebo
(HR 0.68; p¼ 0.02; Figure 4a).9 Survival was not signifi-
cantly improved with erlotinib for patients without EGFR
expression (HR 0.93; p¼ 0.7; Figure 4b).9 Similarly, the
relative risk of death was reduced by 56% for patients with
high EGFR gene copy number receiving erlotinib compared
with placebo (HR 0.44; p¼ 0.008). The response rate was
nearly 10 times as great for patients with a high gene copy
number compared with those with a low copy number
(20 versus 2.4%; p¼ 0.03), and 25% of the patients with a
high gene copy number were alive at 2 years (Figure 5a
and 5b).4 The tests for interaction did not, however, reach
significance for either protein expression or copy number in
that study. In a similar trial (ISEL) that compared the EGFR
TKI gefitinib to placebo with previously treated patients
with NSCLC,10 similar results were reported for protein
expression (Figure 4c and 4d)4 and EGFR gene copy
number (Figure 5c and 5d).9 In that trial, however, both
protein expression (interaction p value 0.049) and gene
copy number (interaction p value 0.045) were found to be
significant predictors of a differential effect of gefitinib
on survival.
Human Epidermal Growth Factor Receptor 2
HER2 is a member of the EGFR family and the
preferred receptor for dimerization with EGFR upon ligand
binding. Preclinical data suggest that HER2 overexpres-
sion may predict response to EGFR TKI therapy. Cappuzzo
and colleagues11 retrospectively evaluated the relationship
between HER2 gene copy number and the response to
gefitinib in 101 patients with NSCLC. Twenty-three
(22.8%) were FISH-positive for HER2, and these
patients had a significantly better response to treatment
(34.8 versus 6.4%; p¼ 0.001) and time to progression
(9.0 versus 2.7 months; p¼ 0.02) compared with FISH-
negative patients. There was also a trend towards
longer survival in the HER2-positive group (20.8 versus
8.4 months; p¼ 0.056). HER2 positivity was associated
with EGFR gene expression and mutations, and patients
whose tumors were positive for both markers experienced
the best clinical outcomes. Conversely, those negative foruthorized reproduction of this article is prohibited.
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Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007 Weighing Tumor Biology for Patients with NSCLCboth markers experienced the worst clinical outcomes. As
with the initial EGFR mutation data, it is not clear whether
HER2 is a prognostic factor in NSCLC. A recent meta-
analysis suggested that HER2 overexpression is associated
with significantly poorer survival at 3 and 5 years, although
the authors urged caution in interpretation because of theCopyright © Adis Data Information BV. Una
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 2007 International Association for the Study of Lung Cancerexclusion of several negative studies that lacked relevant
data.12 Nonetheless, it appears that HER2 status may add to
the predictive value of EGFR expression status with
respect to response to EGFR TKI therapy. It is, however,
not possible to determine whether HER2 status predicts for
a differential effect on survival from those studies becauseuthorized reproduction of this article is prohibited.
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Shepherd and Rosell Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007all patients received treatment with an EGFR TKI and there
was no placebo control arm. Furthermore, amplification of
HER2 is seen rarely in patients with NSCLC (less than
10%), and so at this time, it is not possible to recommend
routine testing for HER2 to select patients for EGFR
inhibitor therapy.
K-ras
K-ras mutations occur in approximately 20–30% of
NSCLC cases.13 As early as 1990, data emerged suggesting
that K-ras mutations are a negative prognostic marker in
NSCLC. A number of studies appeared to confirm this
finding; however, a similar number of studies have failed to
show a negative impact on survival for patients with K-ras
mutant tumors. Data are also conflicting regarding whether
K-ras mutations are a predictive marker for chemoresistance
in early-stage NSCLC.14–17
There is currently interest in exploring the relation-
ship between K-ras mutations and EGFR. K-ras mutations
and EGFR mutations appear to be functionally redundant
in NSCLC because K-ras is a downstream effector of
EGFR signaling. Because of this common pathway, an
activating K-ras mutation could conceivably negate the
effects of an EGFR TKI acting upstream. Several groups
have reported that K-ras mutation is associated with a
lack of sensitivity to EGFR TKI.7,18–20 In the BR.21 trial,
the K-ras genotype could be determined for 206 of the
731 patients.20 The majority had the wild-type genotype,
and 30 (15%) had a K-ras mutation. No significant
difference was seen in the response to erlotinib between
groups, although only one patient (5%) with mutant K-ras
responded to therapy compared with 10 (10.2%) with wild-
type K-ras ( p¼ 0.69). Of interest is the fact that the patient
with mutant K-ras who responded also had a high copy
EGFR number. Patients with wild-type K-ras experienced a
survival benefit that was similar to that associated with
erlotinib in the primary analysis (HR 0.69; p¼ 0.03).
Patients with a mutant K-ras genotype did not, however,
appear to obtain a survival benefit from erlotinib (HR 1.67;
p¼ 0.31). Although informative, these results should be
interpreted cautiously because of the small number of
patients in the analysis.
Using the data from TRIBUTE, Eberhard and
colleagues7 demonstrated that mutations in K-ras and
EGFR rarely occur together. Moreover, they found that
survival was significantly worse for patients with K-ras-
mutant tumors who received erlotinib with chemotherapy
compared with the other three patient groups. Median
survival was 4.4 months for patients with K-ras mutations
who received erlotinib/chemotherapy compared with
13.5 months for patients with a K-ras mutation receiving
chemotherapy alone, 12.1 months for patients with
wild-type K-ras receiving erlotinib/chemotherapy, and
11.3 months for patients with wild-type K-ras receiving
chemotherapy alone. Given the lack of a compelling
scientific explanation for these results, along with the small
number of patients with K-ras mutant disease and the
retrospective nature of the analyses, the finding of a negativeCopyright © Adis Data Information BV. Una
S72interaction between the K-ras mutation and EGFR TKI
therapy must be viewed cautiously. That said, the results are
also instructive; biological markers have the potential not
only to identify patients likely to benefit from certain
therapies, but also those likely to be harmed by certain
therapies.
MOLECULAR MARKERS AND
CHEMOTHERAPY
Excision Repair Cross-Complementing 1
The cytotoxicity of cisplatin occurs mainly as a result of
the formation of platinum-DNA adducts, which lead to cell
cycle arrest and apoptosis. Resistance to cisplatin is related
to the removal of these adducts by an innate, genetically
determined DNA repair system.21 The nucleotide excision
repair system is crucial to repairing cisplatin-induced DNA
damage and several major DNA repair pathways exist.
The excision repair cross-complementing 1 (ERCC1) gene
product is the nucleotide excision repair system enzyme
responsible for recognizing platinum adducts. High tumor
levels of ERCC1 messenger RNA are associated with
platinum resistance in human ovarian and gastric cancer
specimens.22,23 Low levels of ERCC1 mRNA have been
shown to be associated with significantly longer overall
survival for NSCLC patients receiving cisplatin/
gemcitabine compared with those with high levels
(61.6 versus 20.4 weeks; HR 0.32; p¼ 0.005).24 A recent
retrospective analysis of data from the International
Adjuvant Lung Cancer Trial (IALT), a randomized phase
III trial that demonstrated a significant survival benefit for
adjuvant cisplatin-based chemotherapy compared with
observation in patients with completely resected NSCLC
further supports the potential of ERCC1 as an important
marker of platinum sensitivity.25 In that analysis, patients
with ERCC1-negative tumors who received chemotherapy
had prolonged survival compared with their counterparts in
the control group (HR 0.65; p¼ 0.002).25 Conversely,
survival did not differ between treatment arms for patients
with ERCC1-positive tumors (HR 1.14; p¼ 0.40), sug-
gesting that these patients were relatively resistant to the
chosen chemotherapy. A standard protocol for immunohis-
tochemical staining for ERCC1 was used for the IALT trial
analysis. Although confirmation by independent studies is
necessary, this immunohistochemistry protocol has the
potential to be widely applicable and utilized in most
pathology laboratories.
Rosell and colleagues26 from the Spanish Lung Cancer
Group conducted the first randomized trial prospectively to
assess the impact of using ERCC1 protein expression levels
to guide therapy. In the Genotypic International Lung Trial
(GILT), patients in the experimental, or genotypic, arm were
assigned to therapy based on ERCC1 mRNA tumor levels.
Patients with advanced NSCLC were randomly assigned
1 : 2 to a control arm consisting of docetaxel/cisplatin or to
the genotypic arm. Patients in the genotypic arm with low
ERCC1 mRNA levels received docetaxel/cisplatin, whereas
those with high levels received docetaxel/gemcitabine.uthorized reproduction of this article is prohibited.
 2007 International Association for the Study of Lung Cancer
TABLE 2. Interim Results of GILT.26
Control Arm Genotypic Arm
A1 Low ERCC1
(n¼ 55)
A2 High ERCC1
(n¼ 23)
B1 Low ERCC1
(n¼ 99)
B2 High ECC1
(n¼ 61)
Overall response rate 26 (47.3%) 6 (26.1%) 56 (56.6%) 23 (37.7%)
Complete response 4 (7.3%) 1 (4.3%) 1 (1%) 2 (3.3%)
Partial response 22 (40%) 5 (21.7%) 55 (55.6%) 21 (34.4%)
Stable disease 23 (41.8%) 13 (56.5%) 32 (32.3%) 26 (42.6%)
Progressive disease 6 (10.9%) 4 (17.4%) 11 (11.1%) 12 (19.7%)

p¼ 0.02 (B1 versus B2 and A arms by logistic regression).
Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007 Weighing Tumor Biology for Patients with NSCLCPreliminary results were reported in 2005 (Table 2).
Significantly more patients in the genotypic treatment
arm with low levels of ERCC1 responded to therapy than did
patients in the control arm or the genotypic arm with high
levels of ERCC1 ( p¼ 0.02). When patients in the control
arm were evaluated according to ERCC1 level, those with
low levels had a better response to docetaxel/cisplatin than
did those with high levels, consistent with the hypothesis
that higher ERCC1 levels are associated with platinum
resistance. At this first analysis, patients in the genotypic
arm who had high ERCC1 levels did not respond to
docetaxel/gemcitabine as well as expected. These patients
tended to be older than those in the other groups ( p¼ 0.027)
and twice as many had squamous cell carcinoma (43 versus
approximately 20% in the other groups; p¼ 0.009). In the
final analysis, the objective response rate in the combined
genotypic arm was 50.7%, which was significantly greater
than the 39.3% response rate ultimately seen in the control
arm ( p¼ 0.024). This improvement in response did not,
however, translate into a significant improvement in
survival.
Ribonucleotide Reductase Subunit M1
Ribonucleotide reductase subunit M1 (RRM1) is
another potential biomarker for predicting response to
chemotherapy, particularly gemcitabine. Ribonucleotide
reduction is essential to DNA synthesis. Ribonucleotide
reductase converts ribonucleotide 50-diphosphate to
deoxyribonucleotide 50-diphosphate, whereas gemcitabine
competes with ribonucleotide 50-diphosphate for incorpora-
tion into DNA. The overexpression of ribonucleotide
reductase would be expected to interfere with the efficacy
of gemcitabine, and preclinical studies have supported this
hypothesis. The overexpression of ribonucleotide reductase
has been observed in gemcitabine-resistant oropharyngeal,
leukemia, and NSCLC cell lines.27–29 Moreover, in lung
cancer cell lines that were modified to over or underexpress
RRM1, sensitivity to gemcitabine was highest when RRM1
expression was low and resistance was seen when RRM1
expression was high.30
Clinical trial data support these preclinical observations.
The Spanish Lung Cancer Group reported that among patients
with advanced NSCLC who were treated with gemcitabine/
cisplatin, median survival was significantly longer for thoseCopyright © Adis Data Information BV. Una
 2007 International Association for the Study of Lung Cancerwhose tumors had low expression levels of RRM1 mRNA
compared with those with high expression levels (13.7 versus
3.6 months, p¼ 0.0009).31 The expression of RRM1 mRNA
was strongly correlated with ERCC1 mRNA expression
( p< 0.001). Bepler and colleagues30 at the H. Lee Moffitt
Cancer Center also demonstrated that RRM1 expression is
predictive of response to gemcitabine. They found that RRM1
expression was significantly inversely correlated with the
magnitude of disease response in 30 patients with locally
advanced NSCLC who received induction chemotherapy
with gemcitabine and carboplatin. They also recently
completed accrual to a phase II clinical trial that assigns
patients with advanced NSCLC to therapy based on
biomarker expression levels.32 Patients with low ERCC1
expression received platinum-based therapy: carboplatin/
docetaxel for those who also had high RRM1 expression or
carboplatin/gemcitabine for low RRM1 expression. Patients
with high ERCC1 expression received docetaxel-based
therapy: docetaxel/vinorelbine for high RRM1 expression
or docetaxel/gemcitabine for low RRM1 expression. Out-
comes of interest included response rates and progression-free
and overall survival.
Beta-Tubulin
The taxanes exert antitumor activity by interfering with
microtubule dynamics. By binding to beta-tubulin, one of
the major components of microtubules, the taxanes
ultimately produce growth arrest at the G2-M phase of
the cell cycle. Beta-tubulin occurs in at least six distinct
isotypes in humans, and the overexpression of a particular
isotype, class III beta-tubulin, is emerging as a mechanism
behind taxane resistance.33 High levels of class III beta-
tubulin expression are associated with taxane resistance in
human cancer cell lines, including lung, ovarian, prostate,
breast, and pancreatic cancer.34–37 High levels of expression
have been associated with clinical resistance to taxane
therapy in breast and ovarian cancer patients.38,39 Similar
results were not seen, however, in a trial of postoperative
adjuvant vinorelbine and cisplatin, suggesting that this
marker may be more useful in predicting response to taxanes
than to the vinca alkaloids, which also target the
microtubule.40
To explore further the potential of class III beta-tubulin as
a prognostic or predictive marker in NSCLC, Seve anduthorized reproduction of this article is prohibited.
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TABLE 3. Outcomes for Patients with Advanced and Early-Stage Non-small Cell Lung Cancer Receiving Chemotherapy
by Class III Beta Tubulin Tumor Expression Levels.
Advanced Non-small Cell Lung Cancer
Taxane-treated Gemcitabine-treated
Low Beta Tubulin
(n¼ 22)
High Beta Tubulin
(n¼ 25)
Low Beta Tubulin
(n¼ 17)
High Beta Tubulin
(n¼ 27)
Response rate, % 62 13 33 33
Progression-free survival, days 335 105y 165 140
Overall survival, days 525 206z 334 223
Early-Stage Non-small Cell Lung Cancer
Vinorelbine-treated Observation
Low Beta Tubulin
(n U 72)
High Beta Tubulin
(n U 68)
Low Beta Tubulin
(n U 60)
High Beta Tubulin
(n U 65)
Recurrence-free survival, years Not reached Not reachedz Not reached 1.5
Overall survival, years Not reached 7.8 Not reached 4.3

p < 0.001;
y p U 0.004;
z p U 0.002.
Shepherd and Rosell Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007colleagues33 conducted a retrospective study with data from
patients treated with taxane-based or gemcitabine-based
chemotherapy for advanced NSCLC. Taxane therapy
consisted of paclitaxel with either cisplatin or carboplatin.
Patients in the gemcitabine-treated group received either
gemcitabine alone or in combination with cisplatin or
carboplatin. Among the 45 evaluable paclitaxel-treated
patients, the response rate was 37.5%. All clinical outcomes
were significantly better for paclitaxel-treated patients
whose tumors expressed low levels of class III beta tubulin
(Table 3).33,40 The response rate was five times higher for
patients with low expression, and survival was more than
twice as long, compared with the paclitaxel-treated patients
with high expression levels. Conversely, no such differences
were seen among the gemcitabine-treated patients when
compared by class III beta tubulin tumor expression levels.
These findings provide strong evidence that the over-
expression of class III tumor expression by NSCLC tumor
cells has predictive value for paclitaxel therapy, but is not
itself a prognostic factor.
Seve et al.40 also conducted a sub-analysis of the
JBR.10 trial to determine the impact of class III beta tubulin
on patient outcomes and benefit from adjuvant cisplatin/
vinorelbine. In contrast to the findings in advanced disease
that response rates are higher in patients with low tubulin
expression, findings showed that high class III beta tubulin
expression was associated with a greater survival benefit
from adjuvant chemotherapy (Table 3). The reason for this
discrepancy is not yet known. Similar to findings in advanced
disease, high class III beta tubulin expression was associated
with poor prognosis in surgery-only patients. Remaining
questions include whether patients with low tubulin expres-
sion derive benefit from adjuvant cisplatin/vinorelbine and
whether tubulin status is associated with benefit from otherCopyright © Adis Data Information BV. Una
S74adjuvant regimens. Accordingly, tubulin status cannot yet be
used for patient selection or adjuvant treatments.
In conclusion, the use of tumor molecular markers holds
great promise for customizing therapy and providing
optimal treatment to individual patients. There are currently
a number of effective regimens available for the manage-
ment of patients with advanced NSCLC. In the absence of
specific biological tests to guide the choice of treatment,
many patients are prescribed therapy for which the
likelihood of benefit is unknown. Using clinical character-
istics such as sex or ethnicity may improve the likelihood of
response to EGFR TKI therapy, but it may also erroneously
deny the therapy to patients without the typical character-
istics who could benefit from such treatment. Moreover, not
all patients chosen for EGFR TKI therapy based on
favorable clinical characteristics will experience prolonged
survival with treatment; chemotherapy may be a better
choice for certain patients. It is likely that a panel of tests
will be used in the future to determine not only which
patients are likely to respond to EGFR TKI therapy, but
which patients are likely to experience prolonged survival
with such treatment.
Tumor molecular biology may also potentially play a
role in selecting chemotherapy regimens for individual
patients. Markers have been identified that predict response
to platinum-based therapy, taxane-based therapy, and
gemcitabine, and clinical trials are underway to determine
whether chemotherapy customization based on these
markers improves outcomes. In the future, oncologists will
work closely with colleagues in pathology to evaluate each
patient’s tumor molecular profile and determine an
appropriate, customized treatment plan. It is hoped that
such customized therapy finally may lead to significant
survival gains in this challenging disease.uthorized reproduction of this article is prohibited.
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